BioNTech Results Presentation Deck

BNT312 Phase 1/2: First-in-Human Study of DuoBody-CD40x4-1BB, A Next-Generation Bispecific Antibody Next Generation Immunomodulator Bispecific antibody* combines targeting and conditional activation of CD40 and 4-1BB on immune cells Potential to enhance priming and (re-)activation of tumor-specific immunity ● Patients with relapsed or refractory, advanced or metastatic solid tumors who are not candidate for SoC N~50 ..... 28 Mechanism of action of DuoBody-CD 40x4-1BB T BNT312 dose escalation APC TCR Expansion dose 100 mg MHC-I/II 4-1BB APC CD40 į T Cell Open-label dose-escalation trial with expansion cohorts to evaluate safety and anti-tumor activity Part 1 DuoBody-CD40x4-1BB Tumor Cell Antigen-presenting cell T cell Myeloid cell Natural Killer cell Macrophage DuoBody-CD40x4-1BB SoC, Standard of Care; NSCLC, Non-small Cell Lung Cancer; PDAC, Pancreatic ductal adenocarcinoma; HNSCC, Head and neck squamous cell carcinoma *BNT312 (Gen1042) is partnered with Genmab based on 50/50 sharing of costs and profits LOCAL LYMPH NODES Expansion Cohorts n = up to 40 per cohort Metastatic Melanoma, NSCLC, Colorectal Cancer, PDAC, HNSCC Expansion cohorts in melanoma and NSCLC are currently recruiting NK APC APC TUMOR Safety follow-up visits BIONTECH

View entire presentation